HBW
MRNA icon

Hazlett, Burt & Watson’s Moderna MRNA Stock Holding History

Hazlett, Burt & Watson’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed – – 947
2025
Q3 		$0 Hold
10
– – ﹤0.01% 910
2025
Q2 		$0 Buy
+10
New +$263 ﹤0.01% 839
2024
Q3 		– Sell
-10
Closed -$1K – 739
2024
Q2 		$1K Hold
10
– – ﹤0.01% 684
2024
Q1 		$1K Hold
10
– – ﹤0.01% 683
2023
Q4 		$1K Hold
10
– – ﹤0.01% 658
2023
Q3 		$1K Sell
10
-45
-82% -$5.02K ﹤0.01% 685
2023
Q2 		$7K Buy
55
+14
+34% +$1.87K 0.01% 517
2023
Q1 		$6K Buy
+41
New +$6.76K ﹤0.01% 505
2022
Q3 		– Sell
-15
Closed -$2K – 645
2022
Q2 		$2K Hold
15
– – ﹤0.01% 565
2022
Q1 		$3K Buy
+15
New +$2.52K ﹤0.01% 548

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Hazlett, Burt & Watson's MRNA Position: Q4 2025 in Review

Hazlett, Burt & Watson sold out of Moderna (MRNA) in Q4 2025, closing a stake of 10 shares.

Hazlett, Burt & Watson first reported a position in MRNA in Q1 2022 and held it in 10 quarters. The position peaked at $7K in Q2 2023. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Hazlett, Burt & Watson reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • Hazlett, Burt & Watson sold 10 Moderna shares in Q4 2025.
  • Hazlett, Burt & Watson first reported a position in Moderna in Q1 2022 and held it in 10 quarters.
  • Hazlett, Burt & Watson's Moderna position peaked at $7K in Q2 2023.
  • 672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Hazlett, Burt & Watson's 13F filing for Q4 2025, filed 10 Feb 2026.